Induction of G2M arrest by flavokawain a, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin

Danielle D. Jandial, Lauren S. Krill, Lixia Chen, Chunli Wu, Yu Ke, Jun Xie, Bang H. Hoang, Xiaolin Zi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

HER2/neu positive breast tumors predict a high mortality and comprise 25%-30% of breast cancer. We have shown that Flavokawain A (FKA) preferentially reduces the viabilities of HER2-overexpressing breast cancer cell lines (i.e., SKBR3 and MCF7/HER2) versus those with less HER2 expression (i.e., MCF7 and MDA-MB-468). FKA at cytotoxic concentrations to breast cancer cell lines also has a minimal effect on the growth of non-malignant breast epithelial MCF10A cells. FKA induces G2M arrest in cell cycle progression of HER2-overexpressing breast cancer cell lines through inhibition of Cdc2 and Cdc25C phosphorylation and downregulation of expression of Myt1 and Wee1 leading to increased Cdc2 kinase activities. In addition, FKA induces apoptosis in SKBR3 cells by increasing the protein expression of Bim and BAX and decreasing expression of Bcl2, BclX/L, XIAP, and survivin. FKA also downregulates the protein expression of HER-2 and inhibits AKT phosphorylation. Herceptin plus FKA treatment leads to an enhanced growth inhibitory effect on HER-2 overexpressing breast cancer cell lines through downregulation of Myt1, Wee1, Skp2, survivin, and XIAP. Our results suggest FKA as a promising and novel apoptosis inducer and G2 blocking agent that, in combination with Herceptin, enhances for the treatment of HER2-overexpressing breast cancer.

Original languageEnglish (US)
Article number462
JournalMolecules
Volume22
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Kava
Chalcone
breast
induction
cancer
Cells
Breast Neoplasms
cultured cells
Cell Line
Phosphorylation
Down-Regulation
phosphorylation
apoptosis
Apoptosis
multiple docking adapters
proteins
Growth
Cell Cycle Checkpoints
flavokawain A
Trastuzumab

Keywords

  • Flavokawain A
  • HER2 overexpression
  • Resistance to apoptosis

ASJC Scopus subject areas

  • Medicine(all)
  • Organic Chemistry

Cite this

Induction of G2M arrest by flavokawain a, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin. / Jandial, Danielle D.; Krill, Lauren S.; Chen, Lixia; Wu, Chunli; Ke, Yu; Xie, Jun; Hoang, Bang H.; Zi, Xiaolin.

In: Molecules, Vol. 22, No. 3, 462, 01.03.2017.

Research output: Contribution to journalArticle

Jandial, Danielle D. ; Krill, Lauren S. ; Chen, Lixia ; Wu, Chunli ; Ke, Yu ; Xie, Jun ; Hoang, Bang H. ; Zi, Xiaolin. / Induction of G2M arrest by flavokawain a, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin. In: Molecules. 2017 ; Vol. 22, No. 3.
@article{14c3b24b5ccd478ca85f3edd2d882d61,
title = "Induction of G2M arrest by flavokawain a, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin",
abstract = "HER2/neu positive breast tumors predict a high mortality and comprise 25{\%}-30{\%} of breast cancer. We have shown that Flavokawain A (FKA) preferentially reduces the viabilities of HER2-overexpressing breast cancer cell lines (i.e., SKBR3 and MCF7/HER2) versus those with less HER2 expression (i.e., MCF7 and MDA-MB-468). FKA at cytotoxic concentrations to breast cancer cell lines also has a minimal effect on the growth of non-malignant breast epithelial MCF10A cells. FKA induces G2M arrest in cell cycle progression of HER2-overexpressing breast cancer cell lines through inhibition of Cdc2 and Cdc25C phosphorylation and downregulation of expression of Myt1 and Wee1 leading to increased Cdc2 kinase activities. In addition, FKA induces apoptosis in SKBR3 cells by increasing the protein expression of Bim and BAX and decreasing expression of Bcl2, BclX/L, XIAP, and survivin. FKA also downregulates the protein expression of HER-2 and inhibits AKT phosphorylation. Herceptin plus FKA treatment leads to an enhanced growth inhibitory effect on HER-2 overexpressing breast cancer cell lines through downregulation of Myt1, Wee1, Skp2, survivin, and XIAP. Our results suggest FKA as a promising and novel apoptosis inducer and G2 blocking agent that, in combination with Herceptin, enhances for the treatment of HER2-overexpressing breast cancer.",
keywords = "Flavokawain A, HER2 overexpression, Resistance to apoptosis",
author = "Jandial, {Danielle D.} and Krill, {Lauren S.} and Lixia Chen and Chunli Wu and Yu Ke and Jun Xie and Hoang, {Bang H.} and Xiaolin Zi",
year = "2017",
month = "3",
day = "1",
doi = "10.3390/molecules22030462",
language = "English (US)",
volume = "22",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Induction of G2M arrest by flavokawain a, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin

AU - Jandial, Danielle D.

AU - Krill, Lauren S.

AU - Chen, Lixia

AU - Wu, Chunli

AU - Ke, Yu

AU - Xie, Jun

AU - Hoang, Bang H.

AU - Zi, Xiaolin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - HER2/neu positive breast tumors predict a high mortality and comprise 25%-30% of breast cancer. We have shown that Flavokawain A (FKA) preferentially reduces the viabilities of HER2-overexpressing breast cancer cell lines (i.e., SKBR3 and MCF7/HER2) versus those with less HER2 expression (i.e., MCF7 and MDA-MB-468). FKA at cytotoxic concentrations to breast cancer cell lines also has a minimal effect on the growth of non-malignant breast epithelial MCF10A cells. FKA induces G2M arrest in cell cycle progression of HER2-overexpressing breast cancer cell lines through inhibition of Cdc2 and Cdc25C phosphorylation and downregulation of expression of Myt1 and Wee1 leading to increased Cdc2 kinase activities. In addition, FKA induces apoptosis in SKBR3 cells by increasing the protein expression of Bim and BAX and decreasing expression of Bcl2, BclX/L, XIAP, and survivin. FKA also downregulates the protein expression of HER-2 and inhibits AKT phosphorylation. Herceptin plus FKA treatment leads to an enhanced growth inhibitory effect on HER-2 overexpressing breast cancer cell lines through downregulation of Myt1, Wee1, Skp2, survivin, and XIAP. Our results suggest FKA as a promising and novel apoptosis inducer and G2 blocking agent that, in combination with Herceptin, enhances for the treatment of HER2-overexpressing breast cancer.

AB - HER2/neu positive breast tumors predict a high mortality and comprise 25%-30% of breast cancer. We have shown that Flavokawain A (FKA) preferentially reduces the viabilities of HER2-overexpressing breast cancer cell lines (i.e., SKBR3 and MCF7/HER2) versus those with less HER2 expression (i.e., MCF7 and MDA-MB-468). FKA at cytotoxic concentrations to breast cancer cell lines also has a minimal effect on the growth of non-malignant breast epithelial MCF10A cells. FKA induces G2M arrest in cell cycle progression of HER2-overexpressing breast cancer cell lines through inhibition of Cdc2 and Cdc25C phosphorylation and downregulation of expression of Myt1 and Wee1 leading to increased Cdc2 kinase activities. In addition, FKA induces apoptosis in SKBR3 cells by increasing the protein expression of Bim and BAX and decreasing expression of Bcl2, BclX/L, XIAP, and survivin. FKA also downregulates the protein expression of HER-2 and inhibits AKT phosphorylation. Herceptin plus FKA treatment leads to an enhanced growth inhibitory effect on HER-2 overexpressing breast cancer cell lines through downregulation of Myt1, Wee1, Skp2, survivin, and XIAP. Our results suggest FKA as a promising and novel apoptosis inducer and G2 blocking agent that, in combination with Herceptin, enhances for the treatment of HER2-overexpressing breast cancer.

KW - Flavokawain A

KW - HER2 overexpression

KW - Resistance to apoptosis

UR - http://www.scopus.com/inward/record.url?scp=85015799787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015799787&partnerID=8YFLogxK

U2 - 10.3390/molecules22030462

DO - 10.3390/molecules22030462

M3 - Article

VL - 22

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 3

M1 - 462

ER -